Pfizer

Companies & Markets

Pfizer secures China nod for obesity drug as generics loom

Pfizer now enters a field dominated by multinational rivals

2026-03-06T07:45:44.000Z

Pfizer has already warned of challenges it expects over the next few years and has said that it does not expect to return to revenue growth until 2029.

Companies & Markets

Pfizer beats Q4 profit estimates on strong drug demand

Robust demand for its heart and oncology drugs helped achieve total sales for the quarter of US$17.56 billion

2026-02-03T13:21:18.000Z

The drugmaker expects adjusted profit of between US$2.80 and US$3 per share for the coming year, below analysts’ average estimate of US$3.05 per share.

Companies & Markets

Pfizer forecasts 2026 profit below expectations on lower Covid product sales

Pfizer has rolled out a sweeping cost reduction programme in response to the drop in Covid-19 sales

2025-12-16T13:33:11.000Z

The US drugmaker is offering about 4.55 million American depositary receipts via an overnight block trade marketed between US$108 to US$111.70 per share.

Companies & Markets

Pfizer looks to sell stake in pandemic vaccine partner BioNTech

The stake sale could be worth about US$508 million for Pfizer

2025-11-13T09:50:41.000Z

Pfizer said it would pay US$86.25 per share in cash, a premium of 3.69 per cent to Metsera’s Friday close.

Companies & Markets

Metsera accepts Pfizer’s US$10 billion bid in ongoing M&A battle

OBESITY drug developer Metsera said on Friday that it had accepted Pfizer’s US$10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and ri...

2025-11-08T04:14:17.000Z

Pfizer is still trying to rebuild in the aftermath of the pandemic, with a cost-cutting programme and planned deals to drive future sales growth.

Companies & Markets

Pfizer boosts profit view as it battles for obesity startup

Its adjusted earnings for the year will be US$3 a share to US$3.15 a share

2025-11-04T13:35:15.000Z

The tussle for Metsera began with discussions between the company and potential acquirers in early 2024, with both Pfizer and Novo Nordisk, the maker of Wegovy and Ozempic, expressing interest.

Companies & Markets

Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid

[BENGALURU] Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s US$8.5 billion bid ...

2025-11-01T01:33:36.000Z